These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29269566)

  • 1. Bortezomib sensitizes thyroid cancer to BRAF inhibitor
    Tsumagari K; Abd Elmageed ZY; Sholl AB; Green EA; Sobti S; Khan AR; Kandil A; Murad F; Friedlander P; Boulares AH; Kandil E
    Endocr Relat Cancer; 2018 Jan; 25(1):99-109. PubMed ID: 29269566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
    Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
    Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
    [No Abstract]   [Full Text] [Related]  

  • 6. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
    Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
    J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
    Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
    Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin C sensitizes BRAF
    Su X; Li P; Han B; Jia H; Liang Q; Wang H; Gu M; Cai J; Li S; Zhou Y; Yi X; Wei W
    J Exp Clin Cancer Res; 2021 Jan; 40(1):34. PubMed ID: 33468157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
    Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
    Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Combinatorial Strategy for Targeting
    Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
    Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
    Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M
    Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
    Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
    J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
    Bonaldi E; Gargiuli C; De Cecco L; Micali A; Rizzetti MG; Greco A; Borrello MG; Minna E
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072194
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAF
    Wang Q; Hao F; Ning L; Sun C
    Histol Histopathol; 2024 Sep; 39(9):1159-1165. PubMed ID: 38284248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
    Liu R; Liu D; Xing M
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.